The biopharmaceutical company Thermosome GmbH based at BioM in Martinsried has completed its first financing round of 1.9 million euros. Investors in this financing round are Bavaria Capital the High-Tech Gründerfonds (HTGF) and a group of experienced business angels.
In addition to the investment amount of 1.9 million euros Thermosome receives over the project period of three years 2.7 million euros Funding through a recently approved project of the Federal Ministry of Education and Research. Dr. Georg Ried, Managing Director of Bavaria Capital, explains the decision for Thermosome:
“This is a highly innovative and economically promising business concept, to be there experienced founding team with excellent network now fills with life.”
Name-giving nanocarriers
The company is developing a novel drug delivery platform technology based on temperature-sensitive nanocarriers, known as thermosomes. When administered intravenously, the nanocarrier protects healthy tissue from interactions with the drug. Compared to conventional drug delivery, this allows for up to 15 times higher local drug concentrations in diseased tissue while simultaneously reducing side effects. Monika Steger, Investment Director at Bayern Kapital, adds:
“We are pursuing the goal of Translation of outstanding academic research into Bavarian high-tech companies like Thermosome and are absolutely convinced of the commercial potential of the Thermosome GmbH."
Since its founding in 1995, Bayern Kapital has invested more than 220 million euros in equity capital in around 240 innovative, technology-oriented companies from various sectors.
